{"entity":{"id":"erasca","kind":"company","name":"Erasca","aka":[],"tldr":"Erasca develops pills that shut down the RAS signalling pathway, one of the most common drivers of cancer. Its two lead drugs aim to block all forms of RAS or KRAS rather than a single mutation.","summary":"Erasca is a San Diego clinical-stage company focused on RAS/MAPK pathway-driven cancers. Its lead candidates are ERAS-0015, a pan-RAS molecular glue in the phase 1 AURORAS-1 trial in RAS-mutant solid tumours, and ERAS-4001, a pan-KRAS inhibitor in the phase 1 BOREALIS-1 trial in KRAS-mutant solid tumours. Earlier programmes include ERAS-007 (an ERK inhibitor, phase 1b/2 HERKULES-3 in colorectal cancer combinations) and ERAS-801 (phase 1 THUNDERBOLT-1 in recurrent glioblastoma), while the company is exploring strategic alternatives for ERAS-12, an EGFR domain 2/3 bispecific antibody. Erasca completed its Nasdaq IPO in July 2021 with gross proceeds of 345 million US dollars and has since completed several follow-on offerings.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.erasca.com/"},{"label":"Pipeline","url":"https://www.erasca.com/pipeline/"},{"label":"IPO closing 8-K (SEC)","url":"https://www.sec.gov/Archives/edgar/data/1761918/000119312521219642/d81810d8k.htm"}],"tags":[],"related":[],"cancers":["colorectal","glioblastoma"],"sections":["targeted-therapy"],"technologies":["kras-inhibitors","kinase-inhibitors"],"targets":["kras"],"drugs":["naporafenib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year and follow-on offering amounts not sourced. Naporafenib is not listed on the current pipeline page."],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://www.erasca.com/","ticker":"ERAS","stage":"public","investors":["arch-venture-partners"],"funding":[{"round":"IPO","year":2021,"amountUsd":345000000,"source":"https://www.sec.gov/Archives/edgar/data/1761918/000119312521219642/d81810d8k.htm","note":"21,562,500 shares at 16 US dollars including full exercise of the underwriters' option; closed 20 July 2021"}]},"route":"/companies/erasca/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"drug":[{"id":"naporafenib","kind":"drug","name":"Naporafenib","route":"/drugs/naporafenib/"}],"company":[{"id":"arch-venture-partners","kind":"company","name":"ARCH Venture Partners","route":"/companies/arch-venture-partners/"}],"trial":[{"id":"seacraft-2","kind":"trial","name":"A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)","route":"/trials/seacraft-2/"}]}}